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Foreword
The European Monitoring Centre for Drugs and Drug Addiction has great pleasure in
presenting its tenth General report of activities to the European Parliament, the Council of the
European Union, the European Commission and the Member States, following its adoption by
the Management Board in June 2005.
The report provides a retrospective account of the EMCDDA's activities and accomplishments in
2004 at the start of its fourth three-year work programme (2004–2006) and ten years after its
establishment in Lisbon.
The 2004–2006 work programme defines a flexible and phased framework in which to
consolidate and develop the EMCDDA's achievements while taking into account the specific
challenges posed by enlargement and allowing for the incorporation of EU priorities arising
from a new strategy and action plan. It also keeps in step with the capabilities of Member
States and Reitox national focal points to finance and undertake national work in the drugs'
field. The operational objectives focus on two priorities – monitoring and thematic analysis of
the drugs phenomenon. A series of accompanying objectives aim to improve the EMCDDA's
effectiveness by increasing scientific standards and quality, evaluating the relevance of our
objectives and outputs, gaining better visibility and recognition for the added value we provide,
and better integrating our work with other European institutions and bodies in the field.
In 2004, enlargement was at the forefront of our work – with the early months spent fine tuning
processes to accommodate the ten new Member States fully into EMCDDA activities on 1 May. I
am pleased to say that thanks to the thorough preparatory work undertaken in preceding years – 
in particular the introduction of a new operating framework and revised reporting system and
a range of institution and capacity building activities – that it turned out to be a smooth and
successful transition.
The EMCDDA had been called upon by the Commission to assist with the evaluation of the EU
action plan (2000–2004) by producing two 'snapshots' of the EU drug situation at the plan's
start and close. These snapshots were designed to help trace trends between the two study
points and shed light on the progress of the EU targets. 2004 culminated with the publication of
the second 'snapshot' that provided valuable information with which to determine future
strategic actions on drugs in the EU.
Relations with our EU partners were further intensified through collaboration with the Committee
on Citizens' Freedoms, Rights, Justice and Home Affairs of the European Parliament on the
presentation and launch of our Annual report. In a strategy to increase the impact and visibility
of the report, we boosted the national component by inviting national representatives to the
presentation where they were able to intervene on the content of the report alongside members
of the Committee. We also encouraged Member States to organise simultaneous national
events, and those that did so report positive results. Overall, this year's report was perceived as
the best EMCDDA report ever, so our ongoing efforts to improve its quality and relevance for
policy makers appear to be paying off.  
At the end of 2004, we said goodbye to Georges Estievenart, Director of the EMCDDA since
July 1994. Mr Estievenart led the Centre from its inception to the authoritative information
centre it has become today. On behalf of the EMCDDA Management Board and staff I would
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like to thank Mr Estievenart for his 10 years of investment and achievement for which he should
feel proud. His vision will surely continue through the work of the EMCDDA for many years to
come. 
At the close of this challenging year, I would like to express my heartfelt thanks to the
colleagues on the Management Board and the Bureau and staff of the Centre as well as the
national focal point staff and members of the Scientific Committee for their constant support
and dedication which has enabled the Centre to deliver the priorities defined and continue to
improve its services and products.
Marcel Reimen
Chairman of the EMCDDA Management Board
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Introduction
Activity in 2004 concentrated on the first phase of implementation of the 2004–2006 work
programme. In order to ensure that targets were met coherently across the agency, we defined
four horizontal priorities: enlargement, consolidating conditions for monitoring and analysis,
devising a data storage and retrieval system, and streamlining reporting.
Preparation for the arrival of the ten new Member States had been the focus of our work for
some years with assistance provided through the Phare project 'Participation in the EMCDDA'.
The Reitox Academy training sessions played an important role too in addressing the
heterogeneity that accompanied enlargement by bringing together players, facilitating exchange of
expertise and providing technical support to less experienced countries. I am pleased to say
that these investments paid off and the integration went very smoothly. All grant agreements
entered into force on 1 May 2004 and all new countries were incorporated into the data
collection processes and into the Centre's 2004 outputs. 
Also with enlargement in mind, a new Reitox reporting system had been developed jointly with
the network and implementing this new system formed a second focus of our work in 2004. In
particular, we concentrated on strengthening our capacity to deal with receiving and processing
an expanded data set and also improving our capacity to steer reporting processes by offering
technical support and quality feedback. Analytical skills were enhanced both at the EMCDDA
and focal points through joint methodological work on key indicators and core data sets. The
new reporting system has now become a stable framework for Reitox cooperation.   
Devising a system for storing and retrieving quantitative and qualitative data in different
formats is seen as a prerequisite to moving towards the output-driven, objective-focused
approach defined in our 2004–2006 work programme. In 2004, work commenced on defining
a services-oriented architecture for this system. Initial results included the deployment of a web
content management application which facilitates the online publication of our results, and the
development of online data capture interfaces for epidemiological data sets which facilitate the
submission of data by the focal points. In 2005, work on this priority is expected to gather
pace.
Our fourth priority for 2004 focused on streamlining our reporting of the drug problem and
finding the most effective form for disseminating the information analysed. We concentrated on
rationalising and improving EMCDDA communication products, particularly bearing in mind
the need to reflect developments in an additional ten countries. The Annual report was
restructured and the Statistical bulletin was introduced as a companion publication which
presents the data sets and methodology that underpin the analysis in the report. The graphical
representation of EMCDDA findings also received attention with the development of a tool that
enables graphics to be tailored according to interest. A set of Country situation summaries was
devised that provides a brief synopsis of up-to-date trends and core characteristics of the state
of the national drug problem and responses to it, thereby filling another information gap that
we had identified. 
The EU action plan on drugs demonstrates the political commitment to developing effective
responses to a shared problem and the EMCDDA had been involved in the evaluation process
of the 2000–2004 action plan for some years. 2004 saw the culmination of the work with the
publication of the report '1999–2004 Snapshot', achieved in collaboration with Europol. The
report examines the level of achievement of the six political targets of the EU drug strategy and
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action plan during the period under consideration. The report was accompanied by ten
thematic papers each addressing different aspects of activities in the drugs field in the Member
States and EU during the period 2000–2004.
The year culminated with the launch of our Annual report on the state of the drugs problem in
the European Union and Norway – our first ever consolidated report with data from 25
countries and published in 20 languages. We were able to present the report and its findings to
the Committee on Citizens' Freedom and Rights, Justice and Home Affairs of the European
Parliament prior to its launch in Brussels. National launches in several Member States served to
heighten its visibility and impact. 
The year 2004 was demanding on us all due to a considerable increase in work without an
accompanying increase in resources. However, we are proud of what we managed to achieve
and look forward to further improving our data collection and analysis methods in the coming
year to deal more effectively with the enlarged data set we need to process. I take this
opportunity to thank all those who contributed to the results accomplished.
Wolfgang Goetz
Director, EMCDDA
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Chapter 1
Chapter 1
Main achievements compared with the objectives of
the 2004 work programme
The 2004–2006 work programme set out ambitious challenges and targets for the
EMCDDA. In order to ensure that these targets were met across the agency, four horizontal
priorities were identified for the 2004 work programme:
• to incorporate the acceding and the candidate countries into EMCDDA activities,
particularly facilitating the exchange of expertise and providing support to less
experienced performers;
• to consolidate the conditions for monitoring and analysis, with special attention to the
implementation of the new Reitox reporting system;
• to define and set up a computer-based data storage and retrieval system for qualitative
and quantitative information in different formats; and
• to streamline reporting on the drug phenomenon.
The activities of each EMCDDA programme were oriented towards contributing primarily to
the implementation of the above-mentioned priorities which were organised in four cross-
programme priority projects.
Priority 1 – Enlargement
The principal objective of the enlargement priority was to integrate the acceding countries into
Reitox activities and its co-financing scheme. This objective was met and all grant agreements
were approved and entered into force on 1 May 2004.
Another focus was to ensure that the enlargement countries were integrated into the data
collection process (i.e. the inputs). National reports and standard tables were submitted by all
new Member States except for Slovakia and quality feedback on their inputs was provided to
each of them. Furthermore, an addendum to the grant agreements was awarded to Cyprus and
Malta to accelerate implementation of the treatment demand indicator (TDI).
It was also important to integrate acceding and candidate countries into publications (i.e. the
outputs). Data from the new Member States was integrated into all reports. For the first time, a
consolidated Annual report with data from the 25 Member States was produced and also a
Statistical bulletin. A set of country situation summaries was developed for the EMCDDA
website which includes a brief overview of the drug situation in the Member States and a set of
relevant links.
A special effort was made to give visibility to the new countries in communication and
dissemination activities and particularly in the launch of the first consolidated Annual report
where the EMCDDA provided technical support to the national launches in Cyprus, Malta and
Hungary.
Steps were also taken to ensure that all new Member States participated fully in the statutory
bodies. 
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Continued cooperation and assistance was provided to candidate countries. The final activity
report of the Phare project ‘Participation in the EMCDDA’ was approved by the European
Commission. The EMCDDA provided project management and financial management support
to this project – a project that assisted greatly in preparing the new countries for participating
in EMCDDA activities. A new Phare project, to be implemented in 2005 was approved by the
European Commission for Bulgaria and Romania. And the EMCDDA received the first visit of a
Croatian delegation in September, together with Polish regional coordinators. An agreement
was also reached with TACIS for the organisation of a new Reitox Academy TACIS Foundation
Course in Ankara in September 2004.
Priority 2 – Consolidating the conditions for monitoring and
analysis 
Under this priority, particular attention was paid to implementing the new Reitox reporting
system. The elements that make up this package are the Reitox operating framework, Reitox
reporting structure, Reitox reporting tools, and Reitox grant agreements.
The first main objective focused on strengthening EMCDDA capacity for receiving, processing
and retrieving data from focal points and also improving the capacity of the EMCDDA to steer
reporting processes by offering technical support and quality feedback. 
The heads of focal points meetings, expert meetings and analytical workshops as well as Reitox
Academy courses, workshops and national actions that had been planned took place. Reitox
grant agreements were concluded and implemented with all 25 EU Member States. However,
the number of national focal points that participated in the tasking process was not sufficient.
For this reason, this exercise, which should have led to a three-year work programme for
national focal points, was interrupted. 
The new Reitox reporting structure has become the stable framework for Reitox cooperation as
was expected. The analytical skills in focal points and the EMCDDA were further developed and
the joint methodological developments of key indicators and core data sets continued. The
progress made can be seen in the better quality of the national data and information inputs,
assessed as such by the EMCDDA, and also in the perception of the Annual report, which the
different target audiences considered to be the best ever.
The second main objective for this horizontal priority concentrated on enhancing the quality
management of reporting, to improve data quality, comprehensiveness, reliability and
comparability. To this end, the quality of inputs received at the end of 2003 was assessed and
the results were discussed both bilaterally with national focal points and also during the May
heads of focal points meeting. (For further details see the Reitox and Enlargement section of this
report.) The new Member States that had provided their 2003 inputs as acceding countries
were incorporated into the quality assessment process for the first time. For this reason, their
reactions to the EMCDDA quality feedback were given special attention. 
The reporting guidelines for 2005, including the ones for the new reporting tools and the
selected issues, were prepared jointly with the national focal points throughout the year, further
developed at a special meeting on reporting and approved in the November heads of focal
points meeting. (Further details on this are given in the Reitox/Enlargement section of this
report.)
The last objective of this priority was to improve non Reitox data collection schemes via
networks and international organisations. Improvements included: a more lively formula for the
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network meeting of the legal correspondents, with presentations made by national
representatives on significant legal changes in 2004; and the user friendliness of the main ELDD
products as well as streamlined updating facilities.
Data collection and exchange expanded with:
• the Commission in the framework of the EU action plan evaluation exercise (exchange of
data on the targets related to supply reduction for the Snapshot);
• UNODC on information and data on laws and jurisprudences, crime and supply as well as
on substance abuse treatment and care for women;
• WHO/EURO on health in prisons and mental health.
Cooperation was further intensified with the following European transnational networks: 
• European Crime Prevention Network (EUCPN); 
• European Network of Social Inclusion and Health (ENSIH);
• European Network on Drug Services in Prison (ENDSP);
• Central and Eastern Europe Network on Drug Services in Prison (CEENDSP);
• WHO/EURO Network Health in Prisons (HIPP);
• European Red Cross and Red Crescent Network on HIV/AIDS (ERNA).
Priority 3 – Implementing a data storage and retrieval system
Implementing a system for storing and retrieving quantitative and qualitative data in different
formats is seen as a prerequisite to moving towards an output-driven, objective-focused
approach. The development of such a system was set out as a key element in the 2004–2006
work programme.
The system will serve the strategic needs of the EMCDDA in data collection, information
management and dissemination channels. It will integrate, as much as possible, the existing
data collection tools, databases and web sites. From a technical point of view, it will be based
on the EMCDDA IT infrastructure and reflect the methodological needs of handling the
information sets required for the EMCDDA key task of reporting on the drug situation.
During 2004, work commenced on defining a services-oriented architecture. As part of this
process, the EMCDDA information systems with Internet presence were consolidated through the
deployment of a web content management application (CMA). Other development and
procurement activities carried out to build the foundation for this project included: the definition
of a sub project ‘Knowledge Base (KB) Foundations Definition: Semantic WEB, EMCDDA
Thesaurus, Taxonomy, Ontology’; the procurement and deployment of metadata service
prototype to support the whole infrastructure; and the implementation of a prototype installation
for a future information repository based on a native XML database (Software AG’s Tamino).
Development of the online data capture interfaces commenced with the Epidemiological
Information System on Drugs Data (EISDD). An online, server based, data entry system for one
standard table was implemented and a second specified. New generation graphical tools for
national managers supporting DSRS/KB formats comprise another sub project that was
identified but still has to be started. Limited product evaluation was carried out on a
documentation management service and variety of small exploratory prototypes covering
possible application architectures, client tools, and document schema definition were also
tested.
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Priority 4 – Streamlining reporting on the drug phenomenon
This priority concentrated on rationalising and improving EMCDDA communication products
and ensuring that the EMCDDA information and data resources were used effectively – the
principal aim being to provide relevant and focused outputs for key target audiences (policy
makers, EU bodies, specialists, media) on the drug phenomenon. In particular, a more
integrated approach was sought reshaping the products’ format and balance of content to
better suit target audiences.
Emphasis was placed on integrating into EMCDDA outputs the increased amount of data
collected and analysed as a result of enlargement. Language policy and the extent of products
also had to be reviewed in this context. 
A seminar was organised in Sintra to review the annual reporting exercise and to define the
products resulting from it. It was decided that a restructured Annual report outlining new
developments by drug, complemented by chapters covering transversal issues (such as
prevention, treatment and crime) would lend clarity to the publication. The graphical
representation of EMCDDA findings also received attention with the development of a tool that
enables data in graphics to be tailored to requirements. 
The contents of the first-ever Statistical bulletin were also defined. The bulletin is intended as a
companion publication to the report and provides a complementary information source. It
supplies the user with the data tables collated by the EMCDDA from the information submitted
by the national focal points Reitox network. These tables constitute the epidemiological basis on
which the report is written and are frequently referenced by it. In addition to the tables of data
and the accompanying graphics, the bulletin gives detailed technical commentaries, notes and
descriptions. 
Country situation summaries were also devised. The purpose of these summaries is to provide
policy-makers, researchers, journalists and the general public with a brief synopsis of up-to-
date data, trends and core characteristics of the state of the national drug problem and
responses to it. The summaries also include selected links, facilitating access to other national
information sources provided by the EMCDDA and its partners. All country situation summaries
were produced by the EMCDDA in collaboration with the Reitox focal points.
The most comprehensive annual reporting package to date was launched in November
comprising of: the streamlined Annual report in 20 languages (printed publication and online
interactive website); the Statistical bulletin website; and the Country situation summaries.  
Another focus of this priority was to improve the structure and content of the EMCDDA
websites. A content management application (CMA) was developed to facilitate authoring of
new content and to streamline navigation and style elements. The contents of the various
websites were transferred and organised in a more user friendly and accessible structure that
gives better visibility to EMCDDA work results and provides a more cohesive picture of the
drugs problem. Work commenced on developing thematic sub sites as an additional outlet for
the quantitative and qualitative information collected and analysed.   
Thematic, topic-based products (policy briefings, scientific and technical papers) were produced
(see Annex on outputs) as well as the ‘1999-2004 EU Snapshot’ accompanied by 10 thematic
papers.
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Chapter 2
Overview of activities by programme
Monitoring the drug situation
Objectives of the programme
The central objective of this programme is to provide a reliable analysis of the nature and
dynamics of the European drug situation. This task requires ongoing work to improve the
quality and comparability of information on illicit drug use. The activities of the programme
therefore are split between analytic and developmental tasks.  
Analytic tasks focus on the synthesis of data from ongoing monitoring exercises and focused
research studies to provide the basis for a European analysis of drug trends. To support this,
developmental work is conducted with Member States to establish comparable methods for
monitoring drug use in key areas (indicators) and to engage with national experts in an
ongoing process of improving data quality and reliability. Many of the ongoing responsibilities
of the programme reflect these needs and, to date, five key indicators have been formally
adopted by the Member States (1). Progress has also been made in developing reporting
standards for core data on social indicators, such as crime and supply, youth and youth trends.
The specific aims of the programme can be summarised as follows:
• to provide an overview of the drug situation in the EU, based on collection and analysis of
the best available data on drug use, supply and health and social consequences and
correlates;
• to improve the comparability and quality of data on prevalence and health consequences
through the implementation in Member States of the five harmonised key indicators and
through the development at EU level of structures and mechanisms to collect, validate,
analyse and disseminate data;
• to identify and conceptualise potential indicators of social consequences and correlates of
drug use and supply;
• to analyse and interpret the significance of quantitative and qualitative data on trends and
differences in prevalence, patterns and consequences of drug use, and assess its implications
for public health and social policies on drugs;
• to enhance the analytical insights that are provided by the data by placing them in a broader
EU context;
• to collaborate with other projects, national focal points, Community bodies and programmes
and other European and international bodies; and
• to disseminate results that are reliable and useful for decision-makers, scientists and
professionals at Community and national level.
(1) The five indicators are: prevalence and patterns of drug use among the general population – population
surveys; prevalence of problem drug use; demand for treatment by drug users; drug-related deaths and
mortality among drug users; and drug-related infectious diseases.
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Activities and results 
Overview of the drug situation 
Epidemiological data from national reports and other sources concerning 29 countries (all
Member States of the European Union, candidate countries and Norway) were analysed and
synthesised to provide a comprehensive overview of epidemiological data for the EMCDDA’s
2004 Annual report. In 2004, the Annual report was reshaped to a more integrated approach,
with chapters by topics and drugs, including data from various areas of the data collection. The
programme contributed to the overview of the drug situation, chapters 3 to 8 (cannabis,
amphetamine-type stimulants, LSD and other synthetic drugs, cocaine and crack cocaine, heroin
and injecting drug use, treatment, crime and prison issues) and to the selected issues on
‘Cannabis problems in context – understanding the increase in European treatment demands’
and ‘Co-morbidity’.
Preparatory work was undertaken to assemble the necessary information for the key issues that
will be addressed in the 2005 Annual report. This included a review of the research literature
on buprenorphine. The guidelines for 2005 national reports were revised on treatment demand
and buprenorphine, gender differences and developments in drug use within recreational
settings. 
The programme set up and coordinated the first issue of the EMCDDA’s Statistical bulletin,
available as an online publication. The bulletin is a companion publication to the EMCDDA’s
Annual report and provides a complementary information source. It supplies the user with the
data tables collated by the EMCDDA from the information submitted by the Reitox network.
These tables constitute the epidemiological basis on which the Annual report is written and are
frequently referenced by it. In addition to the tables of data and the accompanying graphics,
the bulletin provides detailed technical commentaries, notes and descriptions.
An analysis of the drug situation was also prepared (in collaboration with other departments of
the EMCDDA) to support the reflection made in the Snapshot document prepared to assist the
Commission with the progress made in achieving the targets set in the EU action plan
(2000–2004). 
Improving data comparability and quality – five key epidemiological indicators
The data collected, validated and processed for the Annual report were incorporated in the
Epidemiological Information System on Drug Data (EISDD). Work has begun on defining and
setting up a computer-based data storage and retrieval system for qualitative and quantitative
information in different formats. A first test for implementing this online interface for data
collection for the Centre was made with standard table 1 (population surveys).
Work continued in 2004 on the promotion and implementation of the five key harmonised
indicators of drug prevalence and health consequences, in collaboration with the Member
States. This included the organisation of annual EU-level expert groups on each indicator (see
Annex on Technical meetings). 
In 2004, particular attention was given to the acceding and the candidate countries in these
activities, in the framework of the enlargement of the EU, facilitating the exchange of expertise
and providing them with specific support, either through the means of workshops organised
jointly with the annual expert meetings on the key indicators or through capacity development
training sessions, the so-called ‘Reitox Academy workshops’, with national focal points. Reitox
Academy workshops took place in Lisbon on ‘Methods of infectious diseases surveillance
among IDUs’ and in Ljubljana on ‘Problem drug use estimates’. 
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A project report on the analysis of the EMCDDA databank of surveys on drug use was
delivered. A workshop with new Member States and candidate countries was organised to
develop additional instruments for data collection on toxicology. An update of the drug-related
deaths standard protocol was elaborated in consultation with the European expert group. A
project report on ‘Assistance to the EMCDDA in data collection on drug-related deaths
following the EMCDDA protocol for the key indicator’ was finalised. Final reports on a protocol
for screening in drug treatment and analysis of behavioural data were received in the area of
drug-related infectious diseases. Guidelines on incidence estimation were updated and project
reports on ‘Synthetic estimation of problem drug use prevalence in the EU’ and ‘Estimating
incidence of problem drug use in the EU’ were finalised. 
A small expert working group met to consider the further development of the problem drug use
indicator in the context of the changing nature of the EU drug situation. These deliberations led
to a technical paper and discussion at the full expert working group of the problem drug use
indicator. Work is ongoing to broaden this indicator to better reflect polydrug use and patterns
of non opiate based problem drug use.
Cooperation 
There has been cooperation with other European and international bodies, including: 
• the drugs coordination unit of the European Commission for coordination of legal matters.
The EMCDDA contributed to the evaluation of the EU action plan (2000–2004) by the
European Commission with a Snapshot report on situation and responses before and after
the EU drugs strategy to measure the progress achieved in this period of time, and to
examine the areas where efforts need to be increased; 
• Eurostat and Sanco (DG Public Health – health monitoring) of the European Commission.
Activity was continued, in particular in the area of population surveys, drug-related deaths
and mortality among drug users, and drug-related infectious diseases;
• the UNODC (United Office on Drugs and Crime) for streamlining international reporting,
treatment demand and development of international epidemiological systems, and for
collaboration and coordination on activities related to drug-related data on crime and
supply;
• WHO (World Health Organisation), for drug-related deaths, treatment demand and drug-
related infectious diseases indicators; 
• The Pompidou Group of the Council of Europe, on indicator development and polydrug use; 
• Europol for crime and supply data;
• EuroHIV and UNAIDS for the drug-related infectious diseases indicator;
• ONDCP, SAMHSA and CICAD, which participated in a meeting of international
organisations to analyse treatment demand data. 
Developmental areas 
Data collected on crime, prison, global situation on production/trafficking, seizures, price,
purity were analysed. An EU expert meeting and a Reitox Academy workshop were organised
on ‘Crime and supply-related data’. A small expert meeting on drug availability in population
surveys was also organised, which contributed to establishing draft guidelines for a module of
drug availability for population surveys. A scientific paper was produced on ethnicity and
drug use.
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Emerging trends in drug use and drug problems continued to be reviewed, with particular
emphasis on youth trends. A review of drugs research on youth in the new Member States
was drafted, and a new standard table for youth surveys set up. Youth media were
monitored on an ongoing basis, and a report on youth media was drawn up. A database
on European Youth Epidemiology (EYE) was developed for social research. Collaboration
with the ESPAD project (the European School Project on Alcohol and Other Drugs) was
intensified, and data from school surveys analysed for the 2004 Annual report.
Dissemination of results
An edition of the Drugs in focus policy briefing was prepared on the topic ‘Overdose – a major
cause of avoidable death among young people’. An overview of cannabis potency in Europe
was published in the Insights series.
A scientific monograph was published on Hepatitis C and injecting drug use. This publication
provides the first European data on epidemiological trends in injecting drug users, presents
modelling results that give early indications on which interventions could be the most effective at
the population level, as well as estimates of the future costs of healthcare, which of these costs
are avoidable, and the cost-effectiveness of existing interventions such as needle and syringe
exchange and methadone treatment.
Members of the programme contributed to a number of scientific conferences and technical
meetings where the European drug situation was discussed.
Monitoring responses to drug use
Objectives of the programme 
The main objective of this programme is to collect analyse and disseminate information on
national policies, availability and quality of interventions and services related to:
• prevention of drug use, including universal and selective prevention; 
• harm reduction responses to the drug situation, i.e. prevention of infectious diseases and
acute overdose deaths; 
• drug-related treatment and social reintegration, including co-morbidity; 
• prevention of drug-related crime, in particular assistance to drug users in prisons and
alternatives to prison;
• interdiction measures, measures against diversion of chemicals under control and information
on anti-money laundering activities.
The focus of work in 2004 was to improve and consolidate the quality of information through
specific reporting instruments. Quality control and feedback, training and competence
development, particularly in the evaluation of interventions, were other aspects of work in 2004
on quality assurance. Accordingly, the final outcomes were more and better online and paper
reports, publications and thematic analyses, as well as presentations in different fora. 
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Activities and results
Data collection 
Structured questionnaires on community-based prevention (SQ 25), selective prevention (SQ
26), drug-related treatment (SQ 27), social reintegration (SQ 28) and the reduction of acute
drug-related deaths (SQ 29) were adopted for the Reitox reporting system after a thorough
assessment process, including meetings with national focal points. 
A structured questionnaire on alternatives to prison for drug using offenders was prepared
through a meeting of experts. Work on a new thematic area, low-threshold services for drug
users, continued with the organisation of an expert meeting ‘Quality management in low-
threshold services for drug users: tools, quality and coverage’.
A survey was carried out in the EU 15 Member States and Norway to monitor social and
health policies, measures and actions targeting drug users in prisons by the Cranstoun Drug
Services and the European Network on Drugs and HIV/Aids Services in Prisons (ENDSP). A
second survey in the 10 new EU Member States was launched with a contract awarded to the
German Wissenschaftliches Institut der Ärzte Deutschlands (WIAD), and cooperation with the
WHO/EURO on information collection on health in prisons commenced. 
An expert meeting on cannabis supply reduction was organised as a contribution to the
upcoming cannabis monograph.
The programme also contributed to the evaluation of national reports. The data and quality
indicators on universal school-based prevention (intensity, quality control, evidence base,
delivery mode) in Member States and candidate countries were consolidated. 
A glossary on terms used in the guidelines and instruments in the responses area was being
assembled with the objective to standardise the terminology, both within the EMCDDA and for
its partners.
The programme cooperated with Reitox and other programmes to streamline information
collection within the Centre and contributed to the preparation of online questionnaire tools and
the development of an electronic data collection and retrieval system.
European Database on Drug Demand Action (EDDRA)
Performance indicators and targets and a quality assurance plan for the EDDRA database were
implemented. Extensive work was done to assure quality control of new EDDRA entries and
updating of existing ones. The new Member States were supported and encouraged to
contribute to EDDRA activities with assistance from other members in the Reitox network. There
are now national EDDRA managers in all of the new Member States and Romania.
The main focus of the EDDRA annual coordination meeting was to update the questionnaire
tool and a draft version is complete. A new classification model for EDDRA entries was also
developed. 
During 2004, a marketing plan for EDDRA was implemented, the EDDRA website was updated
using the content management tool and extensive new features were added: quick searches,
country lists and recent updates. EDDRA is expecting its 500th entry at the beginning of 2005.
In 2004, EDDRA received a total of 100 files of which 60 were new projects and 40 were
project updates (compared to 103 files in 2003 of which 88 were new projects and 25
updates). So it is clear that this year the focus has been on improving the quality of project
entries. A first entry has been received from the Czech Republic and entries from other new
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Member States are in the pipeline. Over 12 months, the number of monthly site visits to EDDRA
increased by 549%, the number of monthly visitors increased by 463% and visitors who visit the
site more than once a month have increased by 320%. The total number of monthly page views
increased by 168% and the average visit length increased by 50%.
Dissemination of results
Annual reporting
The Reitox national reports 2003 as well as standard tables and structured questionnaires were
processed and analysed for the EMCDDA annual reporting exercise. In specific cases,
information from other sources was collected, classified and analysed. Data in the EU and
international partners’ databases on interdiction measures, measures against diversion of
chemicals under control and information on anti-money laundering activities were also selected
and analysed.
Texts, tables and graphics were drafted for the Annual report printed and online versions, the
selected issue on Co-morbidity was drafted and the programme contributed to the selected issue
on Cannabis. Online tables for the 2004 Annual report included an analysis of the coverage,
quality control and contents of universal school-based prevention and selective prevention. They
gave an improved comparative overview on the degree of development and evidence base of
drug prevention in Member States according to several variables. 
Evaluation of EU action plan
The final evaluation of the EU action plan (2000–2004) included data on responses, for
example an analysis of coverage of needle exchange and trends 2000–2004. A contribution
was made to the specific paper on drug using offenders in the EU which was included in the
evaluation.
Websites
The responses area of the EMCDDA website was thoroughly revised and updated. A range of
reports, online articles, tables and graphics, as well as external links were put on the web. Best
practice documentation piloting a hepatitis resource bank is under development. In the Reitox
country profiles, additional detailed prevention country profiles were added. Work on the
Evaluation Instrument Bank (EIB) continued. It now contains more than 250 evaluation
instruments and the visits to the site increased from 3 000 page views in February to 50 000 in
November.
Training
The structures for an online training module on prevention programming and evaluation for the
EMCDDA website were developed with training strategies and material for training related to
EDDRA and evaluation. Seven intensive training seminars on programming and evaluation
were held in Italy, Spain and Portugal. 
Cooperation with external partners
The EMCDDA was asked to cooperate with the European Commission, DG Sanco to prepare a
call for tender to evaluate the implementation of the Council Recommendation on the prevention
and reduction of health-related harm associated with drug dependence of 18 June 2003. Over
the next two years, EMCDDA data on reduction of drug-related harm will be extensively used
for an inventory on the implementation of a number of concrete measures as recommended by
the Council.
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The partnership with WHO/EURO expanded substantially, particularly in the areas of health in
prisons and mental health. Preparation of a specific work programme as an annex to the
WHO/EURO and EMCDDA Memorandum of Understanding from 1999 commenced.
Other partnerships included:
• expert panel to UNODC publication ‘Substance abuse treatment and care for women: case
studies and lessons learned’ (2003–2004);
• membership in the Task Force of the WHO/EURO Network Health in Prisons (HIPP);
• membership in the Pompidou Group platform on ethics;
• advisory committee of European Network of Social Inclusion and Health (ENSIH) Correlation
Project (2005–2007);
• membership in the European Network on Drug Services in Prison (ENDSP) and Central and
Eastern Europe Network on Drug Services in Prison (CEENDSP) steering groups
• expert in the European drug abuse prevention trial for the implementation of the first
European controlled trial on school-based prevention.
Implementing the 1997 EU joint action on new synthetic drugs 
The activities implemented by the programme in 2004 were in accordance with the 2004–2006
work programme’s key priorities and operational objectives. All activities were designed and
implemented in order to deliver the expected outputs/results in the best possible way. In 2004,
the programme approach was twofold: 
• to ensure timely implementation of all core tasks as stipulated by the 1997 Joint action on
new synthetic drugs, in particular, the early warning system (EWS) on new synthetic drugs
(art. 3);
•to implement specific activities in order to contribute to the achievement of the four
horizontal/cross programme priority projects of the Centre. 
Implementing the core tasks stipulated by the 1997 Joint action 
Permanent collection, analysis and exchange of information on new synthetic drugs through the
European (Reitox) early warning system is a core EMCDDA task assigned by the 1997 Joint
action (art. 3). This is being done in close cooperation with Europol, which ensures relevant
complementary information through its network of national units. 
In 2004, more than 25 substances were actively monitored in the framework of the Reitox early
warning system. These include the nine substances that have been risk assessed since 1998 as
well as a number of substances on which the EMCDDA has obtained information with different
levels of evidence and danger – among them substances from three major groups:
phenethylamines, tryptamines and piperazines. 
In 2004, the Member States submitted 17 formal notifications on new drugs to the EMCDDA.
The notified substances were followed up through analysis and rapid dissemination of
appropriate information to all partners i.e. the national focal points (NFP), Europol, London-
based EMEA and the Commission. Consequently, the relevant new compounds were added to
the list of actively monitored substances for further collection of information and subsequent
analysis. Nevertheless, no scientific risk assessment on new drugs was carried out in 2004,
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since due to the lack of sufficient evidence of public health or social risks, the EMCDDA and
Europol did not request the Commission and the Council to authorise a risk assessment of new
substances.  
Furthermore, based on regular and ad hoc reports submitted by the Member States through the
early warning system, the Joint action programme made information readily available to
partners through updating the existing information sheets (substance profiles) on new synthetic
drugs, creating new sheets and providing structured feedback and summarised information. In
addition, where available, analytical details on new substances were provided to all NFPs in
order to assist their laboratory networks. At the same time the enriched and restructured
information on new substances was prepared for incorporation into the future database on new
drugs (see EDND below). 
As in previous years, the early warning system functioned proactively and, in some potentially
risky and hazardous instances from a public health perspective, beyond the legal scope of the
Joint action. Thus the EWS collected, analysed and distributed information on known drugs,
which are already under international control. For example, information was collected and
disseminated concerning: a major incident of about 60 intoxications, including two
unconfirmed death cases (in four EU Member States – Italy, the Netherlands, Belgium and
France) with cocaine containing high percentage of unusual and potentially hazardous
adulterant – atropine; a number (approximately 100) of fentanyl intoxications and four
suspected death cases in Estonia; appearance of a highly potent amphetamine-derivate – DOB
(brolamfetamine) in Ireland and in the Czech Republic where it involved one death case. On all
these occasions, the EWS demonstrated that it is highly operational, flexible and well equipped
to detect and rapidly respond (in real time) to potential public health threats and emerging
drugs phenomena. In all these instances, the Member States concerned have undertaken to
release alerts to their respective networks, public heath authorities or in some cases to the
general public.
In December 2004, the Joint action programme organised its 4th annual EWS workshop with
the participation of the early warning system correspondents from the Member States, Norway,
the candidate countries as well as the European Commission, Europol and the EMEA. The main
objective of the meeting was to prepare the network for implementation of the extended scope
of the impending new Council Decision to replace the 1997 Joint action through revision of the
EWS reporting tools (in particular, the EMCDDA/Europol reporting form and EWS progress
reports). The final prototype of the EMCDDA’s information system – website and database – on
new drugs (EDND) was also presented and discussed during the workshop. Furthermore, the
workshop enhanced the networking between the EWS partners at European level and the
extension of the system to the new Member States and candidate countries.
In order to increase the knowledge of the national EWS correspondents in scientific matters
related to different properties of synthetic drugs, a component on new drugs was defined and
integrated into the Reitox Academy training programme. The Joint action programme, in
cooperation with Reitox Coordination and the Lithuanian Drug Control Department, organised
an intensive course specifically designed to provide high-level technical training to more than
30 experts from 19 Member States and candidate countries in order to enhance their daily
practice, on 25–26 October 2004 in Vilnius. The course took place in the Lithuanian Parliament
and was opened by the Minister of Health and Chairman of State Drug Control Commission.
Evaluation showed that the training was highly successful and beneficial to all participants. A
training CD ROM has been made available to all NFPs. 
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Finally, the programme team actively contributed and provided regular feedback to the
Commission and the Horizontal Drugs Group of the Council for definition and drafting of the
text of the new Council Decision on the information exchange, risk assessment and control on
new psychoactive substances to replace the 1997 Joint action on new synthetic drugs.
Specific activities related to the four priority projects
Enlargement: incorporate new Member States and candidate countries
In 2004, the programme initiated the formal participation of the ten new Member States in the
collection and exchange of information phase of the 1997 Joint action (art. 3). To enhance this,
(self-)assessment of the national early warning systems in the new Member States was launched
and completed. Based on the conclusions of the assessment, customised technical assistance at
national level was provided. Missions took place to support the national EWSs in the Czech
Republic, Hungary, Lithuania, Bulgaria and Romania.
Consolidate conditions for monitoring/analysis
The process of adapting the EWS monitoring and reporting capacities in view of the new
Council Decision, which extends scope to all new psychoactive (new narcotic and new
psychotropic substances alike) was initiated through a meeting of an ad hoc working group
to assist in the revision of the EWS reporting tools. Furthermore, a meeting took place to
examine the feasibility for extending operation of the EWS towards the implementation of
an early information function i.e. to include identification and monitoring of new trends in
drug use. This was done in cooperation with the Euro-Trend project (coordinated by the
French OFDT), the P1 programme and Reitox coordination. 
Define and set computer-based data storage and retrieval system
By the end of 2004, the European database on new drugs (EDND) – website and database –
had been conceptualised and prototyped. An external contractor had been selected and work
was in progress to create an evidence-based database, which will be dynamically linked to a
newly created extranet. The database will provide access to the specific information collected
through the European-wide EWS and the risk assessments of new synthetic drugs as produced
by the EMCDDA’s Scientific Committee. An information system assistant was recruited to
maintain the operational environment and services of the information system. 
Reporting on drug phenomenon
To increase the focus on new synthetic drugs in the 2004 Annual report, the Joint action
programme prepared a specific sub-chapter (in Chapter 4 Amphetamine-type stimulants, LSD
and other synthetic drugs). Furthermore, two publications which included the four risk
assessment reports carried out at the end of 2003 were prepared and released as follows:
(a) Report on the risk assessment of 2C-I 2C-T-2 and 2C-T-7 in the frame of the Joint action on
new synthetic drugs; (b) Report on the risk assessment of TMA-2 in the frame of the Joint action
on new synthetic drugs. 
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Monitoring national and Community strategies and their impact 
Objectives of the programme 
The work of this programme aims to monitor and describe policies, their framework and their
relevant context; to contribute to policy analysis; and to contribute to policy evaluation. Over
the last few years, two main groups of activities have been developed in order to achieve this.
Monitoring and analysis activities concentrate on coordination mechanisms, national strategies,
European and national legislation, public expenditure and evaluation schemes and tools. The
second group of transversal activities focus on coordinating and designing the EMCDDA’s
contribution to the evaluation of the EU action plan.
Activities and results
Monitoring and analysing policies
Under this area, 2004 has mainly seen the consolidation and continuation of work already
launched in earlier years.
Conceptualisation work continued in the area of public expenditure – though at a moderate
pace as the demands of dealing with this extremely complex issue as well as a restriction on
resources left little room for developmental activities. No expert meeting could be organised in
this area, and despite the late recruitment of a new staff member who dedicated part of his
time to this project and helped to speed up progress in this field, the appropriate scientific
strategy (possible scope of data collected, methodology for harmonised data collection, time
interval for collection, etc.) is still being worked out. Despite these constraints, however, a
valuable report on drugs-related public expenditure by Member States was produced and
transmitted to the European Commission as background information for the evaluation of the
EU drug strategy.
In the area of coordination and strategies, work focused on obtaining a more comprehensive
and detailed picture of these policy instruments. In order to rationalise and thus improve data
collection processes and data quality in this field, a structured questionnaire (SQ) on policy and
institutional frameworks was conceived, developed and assessed by experts and focal points.
(This SQ will be tested in 2005 by the Reitox network.) A first step towards a better
understanding of coordination mechanism practices was also achieved through commissioning
an external study that in 2005 will collate data and review evidence on the identification of
various, appropriate conditions for effective implementation of coordination. More ad hoc
thematic reports (Legal status of drug use study) and scientific articles (on cannabis control for
Toxicodipendencia, PT; on drugs expenditure for Addiction, UK) were also an integral part of
this policy-focused project.
As regards the projects on European and national legislation, a key activity in this programme,
there was fine-tuning and improvement of data presented in the European Legal Database on
Drugs (ELDD). The management of the network of legal correspondents was also enhanced: the
network meeting formula was improved and data collection and study revision/updating
processes were streamlined. This was done with a view to extending the scope of the legal
thematic areas covered by ELDD (including EU and EC legal instruments), to improving the
capacity of ELDD to respond rapidly to a growing number of ad hoc requests from its
audiences (mainly policy makers and media, but also researchers and professionals) and to
coping more efficiently with the increase in workload (in particular with regard to updating
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information within ELDD) resulting from the inclusion of 10 new Member States. More efficient
exploitation of the legal information already available in ELDD was also targeted and several
studies focusing on specific areas/topics were published or prepared (Legal status of drug use
study, reports for the UK on legal status of khat and mushrooms, 2 overview tables on drugs
and the Internet and syringe exchange). A great step forward has been made in the area of
European legislation, with the publication of the ‘EU legislation section’ in the ELDD web site,
offering a comprehensive overview of EU and EC legal instruments in the field of drugs. This
website section dedicated to EU level information goes hand in hand with the release of a study
establishing the state of the art of EU and EC legislation on drugs (to be published at the
beginning of 2005). Several ad hoc working documents requested internally and by some of
the EMCDDA’s audiences were also drafted (for instance, on Russia, on the North-African
countries, and on the North/South regulation).
In most of the areas covered by the projects above, a great deal of effort was directed at
improving the programme’s contribution to the Annual report, concentrating on new
developments and focusing on fresh issues for which the Centre has collated sufficient
information to elaborate interesting retrospective overviews. This can be illustrated in the
field of treatment and social rehabilitation, where an overview on quality assurance
mechanisms in drug-related treatment was published, giving for the first time an insight into
the assessment of treatment quality in Europe. Also worth noting is the Evaluation
Instruments Bank (EIB), which has become a routine activity of the treatment project, leading
to one of the most popular EMCDDA outputs: in this respect, a number of new evaluation
instruments were traced, assessed, and published on the EIB website. Subsequently, the
page views rose from between 3 000 and 6 000 in the beginning of the year to between
20 000 and 50 000 at the end of the year. Work to streamline harmonised data collection
tools was also carried out, and two Structured questionnaires – one on social rehabilitation
and one on treatment – were tested by experts and finally adopted by the Reitox network as
part of the data collection instrument package for 2005. This was a necessary step to pave
the way towards the collection of more structured qualitative information, and therefore
towards better evidence-based reporting on two crucial drug policy areas.
Contribution to the evaluation of the EU action plan (2000–2004)
The second group of activities are transversal activities reflected in the EMCDDA matrix. In this
respect, the programme was responsible for coordinating and designing the EMCDDA
contribution to the evaluation of the EU action plan.
Throughout 2004, the programme worked hard to raise awareness among its target audience
on the usefulness of evaluating drug policies and interventions. The most noteworthy
accomplishments to promote good practice and disseminate technical and methodological
recommendations in this area included the organisation of a specific Reitox Academy, the
publication of a policy briefing on the evaluation of the EU action plan, active participation in
the workshop on this matter in the Dublin Conference organised by the Irish Presidency of the
Council of the European Union, commissioning a study on evaluation mechanisms in some
Member States and drafting a selected issue of the 2004 Annual report on national evaluation.
Above all, the programme contributed to constructing the final evaluation process managed by
the Commission. 2004, the final year for implementing the EU action plan (2000–2004), was a
period of solid achievement in the field of evaluation. 
One of the main products was the ‘1999–2004 Snapshot’ report achieved in collaboration with
Europol and other EMCDDA programmes. This report examines the level of achievement of the
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six political targets of the EU drug strategy and action plan during the period under
consideration. The report was delivered to the European Commission in June 2004 as a direct
contribution to its Communication on the evaluation of the EU action plan (2). 
Ten thematic papers accompanied the report each addressing different aspects of activities in
the Member States and EU in the drugs field in the period 2000–2004: Main lessons from
investigation of evaluation in the drug policy field; Drug strategies and action plans;
Coordination of drug policy; Public expenditure on drugs; Legislative activity; Drug law and
young people; Drug-using offenders; Legal responses to new synthetic drugs; Evolution of EU
budget lines on drugs; Drug provisions in EC external agreements. As such, the coordination of
the EMCDDA’s contribution to the evaluation of the EU action plan and the drafting and/or
supervision of the 10 thematic papers represented the bulk of the programme’s work
programme in 2004.
The Snapshot reports and thematic papers were presented to the Horizontal Drugs Group of the
Council upon the release of the Communication on the evaluation of the EU action plan, and
have, as a whole, certainly contributed to the inter-institutional debate leading to the adoption
by the European Council (16–17 December 2004) of the EU drugs strategy (2005–2012),
which will be included in the Hague Programme and which will serve as a framework for the
future EU action plan to be tabled by the European Commission in the course of the first
semester of 2005.
The programme continued to respond promptly to policy makers needing information and
analysis on any issue of scientific and policy interest. It has therefore maintained its efforts to
develop the specific expertise that allows it to provide, on request, transversal and policy-
focused added value to EMCDDA activities and products.
Reitox and Enlargement 
Objectives of the programme
In 2004, five main objectives were identified: 
• to manage and further develop the Reitox network of EMCDDA partners according to the
‘Operating framework of the Reitox system’;
• to assess the quality of the reports, data and information received at the end of 2003, further
improving the EMCDDA’s quality assurance approach and developing guidelines for 2005
national reporting;
• to draft and publish country situation summaries for the 25 EU Member States and Norway;
• to define and implement a capacity building programme according to the needs of the
national focal points and the EMCDDA’s scientific programmes;
• to manage the integration of the new EU Member States into the EMCDDA work and bodies
and assist the European Commission in moving forward negotiations with Bulgaria, Romania
and Turkey towards EMCDDA membership.
(2) COM (2004) 707 final available at http://europa.eu.int/pol/justice/index_en.htm
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Activities and results
Reitox network development
The formal integration, on 1 May 2004, of the 10 new EU Member States into the cooperation,
information and data flow system between the national focal points and the different EMCDDA
programmes had been prepared for several years and therefore worked smoothly. Meetings of
heads of focal points, including all 29 partner countries, the Commission and the relevant
EMCDDA programmes, took place in Lisbon (2 meetings) and in Warsaw. Furthermore, the
participation of national focal point experts in numerous technical and scientific meetings and
Reitox Academies was organised. 
In 2004, more national focal points provided the EMCDDA with their national reports and data
on time than in previous years. Nevertheless the unsatisfactory way many national focal points
dealt with the agreed September and October deadlines for their inputs to the EMCDDA still
hampered the timely production of EMCDDA key outputs, namely of the Annual report and the
Statistical bulletin. 
After having received the final implementation reports and external audit reports, all 2003
grant agreements were completed through the execution of the final payments. In May 2004,
the new EU Member States also became eligible for Reitox grants. Therefore, in 2004, the
number of grant agreements with national focal points increased from 15 to 25.
From 2004 onwards, the Reitox cooperation between the EMCDDA and its partner countries
should have been given an additional basis – the three-year NFP work programme. However,
due to limited resources and organisational problems, a majority of national focal points did
not establish their national programmes. Given these shortcomings and taking into
consideration that the grant agreements already contain a clear description of the requested
NFP outputs, the EMCDDA accepted in the November 2004 heads of focal points meeting to
interrupt this tasking exercise and to postpone a final decision until the entry into force of the
recasted founding Council Regulation. The latter is supposed to provide a revised definition of
the Reitox network and the role of the national focal points.
Quality 
The quality of the 2003 national reports and the other data and information inputs was
assessed at the beginning of 2004 and in May 2004 the national focal points of all old and
new Reitox partner countries received their detailed quality feedbacks, which, in most cases,
were discussed bilaterally. An overview of the different input qualities received was provided at
the May heads of focal points meeting.
In October 2004, most national focal points met with the EMCDDA for a special meeting on
pertinent reporting and quality assurance issues. The discussions focused on initial experiences
with the implementation of the new ‘Reitox reporting structure’, the EMCDDA proposal for the
guidelines for 2005 reporting, and a review of the current quality assurance approach for
national reports, standard tables and structured questionnaires.
The main part of the reporting guidelines is updated and improved year-on-year, but new
selected issues are added annually, which the EMCDDA identifies on the basis of proposals
from the national focal points and EMCDDA staff. At the November heads of focal points
meeting the reporting guidelines for 2005, including the ones for the selected issues, were
adopted. At the end of 2004, a new questionnaire to be filled out by the EMCDDA project
managers when assessing national inputs was developed.
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Country situation summaries
A new online information source comprising a fresh presentation of data by Member State was
presented in the form of ‘Country situation summaries’ (http://profiles.emcdda.eu.int), which
are illustrated via an enlarged European Union and individual country maps. These brief and
concise overviews on the drug situation in the old and new EU Member States and Norway are
published in the respective national languages as well as in English. They are compiled from
national reports and standard tables, submitted through Reitox and produced in collaboration
with the National focal points. In June 2004, these online sources included Country situation
summaries of all 10 new Member States; the ones of the 15 old Member States and Norway
were added in November 2004. 
Capacity building
The 2004 capacity building programme was developed in close cooperation with the
EMCDDA’s scientific programmes and the national focal points. The Reitox Academy courses
and workshops, which were implemented throughout the year focused on: the EMCDDA’s
contribution to the evaluation of the EU action plan on drugs (2000–2004), data interpretation
and reporting, problem drug use estimates, crime and supply data, new synthetic drugs,
infectious diseases and drug-related deaths. At the request of the European Commission, a
specific Reitox Academy foundation course for TACIS countries on the building of national focal
points and national drug information networks was organised in Ankara, in close cooperation
with the Turkish national focal point and the latter’s twinning partners, Spain and Greece.
More details regarding the 2004 Reitox Academies can be found in the annex on technical
meetings. Former participants find the documents and training materials of past and future
courses and workshops on the Reitox Academy website (http://academy.emcdda.eu.int).
Within the framework of the EMCDDA’s assistance to further developing national networks, a
study visit for the regional Polish drug coordinators was organised. The future Croatian Reitox
partners participated in this event to obtain a first insight into the objectives and work processes
of the EMCDDA and Reitox.
Future enlargements
At the end of 2004, all new EU Member States were actively participating in the work of the
Management Board, but active participation in the Scientific Committee was still limited to six of
them; four nominations for new Scientific Committee members were still outstanding. The move
from 16 to 26 EMCDDA member countries also became visible in the EMCDDA outputs, such
as the Annual report or the above-mentioned Country situation summaries.
Two months after EU membership of the former acceding countries, the Phare project
‘Participation of the candidate CEECs in the EMCDDA’ was successfully concluded. At the end
of the year, preparation work started for a new Phare project, which will foster the participation
of Romania and Bulgaria in EMCDDA activities.
Throughout the negotiations for EMCDDA membership between the European Commission and
Bulgaria, Romania and Turkey, all partners involved frequently consulted the EMCDDA. There
was also regular exchange with Croatia, which, further to being accepted as a candidate
country to the EU, also envisages becoming an EMCDDA member.
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Communication and dissemination 
Publications
The objective of the publications programme is to produce both printed and online publications
addressing the most important aspects of the drugs phenomenon in the EU and Norway and
the acceding and candidate countries. During 2004, this activity was very much linked to the
priority on streamlining information on the drugs phenomenon, with a particular emphasis on
fine-tuning products to fit with the needs of target audiences.
The objectives of the programme include producing a printed publication reflecting the main
results and achievements of the EMCDDA in 2004; publishing the EMCDDA budget in the
official EU journal; consolidating and improving the EMCDDA specialised series (Monographs,
Insights, Manuals and Risk Assessments); and providing a high-quality editorial service.
The 2004 Annual report was coordinated, edited and published in 19 EU languages and
Norwegian. A concerted effort was made to improve the structure and presentation of the
report in order to render the information more accessible to the reader. An expanded online
version in 20 languages was also prepared with interactive graphics. A first Statistical bulletin
providing data underlying the report and methodological commentary and notes was also
produced. 
The EMCDDA published its 2003 General report of activities and four editions (45, 46, 47, 48)
in 5 languages (ES, DE, EN, FR, PT) of Drugnet Europe. The EMCDDA Series were further
developed with an Insights on the potency of cannabis, two Risk assessments and a Monograph
on hepatitis C.
Improving the scientific quality of the information produced has been a long-standing objective
of the EMCDDA and a scientific editor was recruited to work towards this. The various
EMCDDA websites are increasingly used for the dissemination of project reports and summaries
and a considerable amount of time was spent on editing such material for online dissemination.
The content of the main EMCDDA website was restructured and transferred into the new content
management tool. This tool facilitates authoring of new material and enables project sub-sites to
be developed. 
The Snapshot website, which carries the results of the evaluation of the EU action plan
(2000–2004) was developed and published. The Snapshot website offers data on the drug
situation by country as well as downloadable reports and thematic papers.
Media relations and marketing 
Media relations
The EMCDDA’s media relations activity is organised around three strategic objectives: building
sound contacts with journalists; providing media-friendly information (materials/events); and
assessing impact via press monitoring and reviews. Activities in 2004 are listed below in line
with these goals.
News contacts: Press lists/contacts for 26 countries were updated in 2004. Expanded lists for
the 10 new EU Member States paid dividends at the launch of the Annual report in the form of
unprecedented coverage on the product in these countries. 
News materials/events: The EMCDDA produced 11 news releases in various languages
(totalling 94 products); three fact sheets (EN); and news release templates in 13 additional
36
General report of activities 2004
languages. The ‘News and media services’ section of the website was updated following a
2003 external evaluation. A press briefing and conference were held on 24 and 25 November
in Brussels launching the 2004 Annual report. 
News monitoring: Six press reviews were produced (4 quarterly; 1 ad hoc, 1 Annual report).  
The EMCDDA 2003 media relations strategy was updated.
Marketing
The range of EMCDDA promotional literature launched with the new corporate identity in 2003
was further developed in 2004. This included the publication of the EMCDDA general
presentation brochure (2004–2006) in the 10 new EU languages and a promotional brochure
‘EMCDDA online’ in English. Both products were released to mark the launch of the 2004
Annual report. The latter was also displayed on the EU stand at the exhibition ‘Online
Information 2004’.
The joint EU agencies’ brochure, European agencies – working across Europe for you, was
updated and entered production in 23 languages at the end of the year. 
Three promotional mailings were dispatched in 2004 to publicise EMCDDA products to book
reviewers (scientific press). New products were also promoted via Drugnet Europe and the
public website.
Content was provided for a training course ‘Representing the EMCDDA on mission’,
implementing a 2002 proposal. Recommendations will be followed up in 2005.
To adapt to EU enlargement, the Corporate Identity project produced several items to support
the new languages (fonts, logos, templates).  
The Centre hosted an exhibition at the European Parliament to publicise the 2004 Annual
report. An advertisement was produced for The Parliament Magazine in December for the
same purpose. PowerPoint presentations on the report were produced for use at national
launches.
Inter-institutional communication
The EMCDDA collaborated with the Committee on Citizens’ Freedoms and Rights, Justice and
Home Affairs of the European Parliament in the context of the presentation of the 2004 Annual
report on 24 November, the eve of the official press launch. In line with an EMCDDA strategy
to increase the impact and visibility of the EMCDDA Annual report by boosting the national
component, national parliamentarians were invited to the presentation from 26 countries. For
the first time national representatives were able to intervene on the content of the report
alongside members of the above Committee. The presentation was preceded by a reception for
national and European parliamentarians where the EMCDDA described its work.
Seven EU Member States (Cyprus, Greece, Hungary, Lithuania, Malta, Poland and Portugal)
organised national presentations of the Annual report. Three of them (Cyprus, Lithuania and
Malta) placed their own national drug situation in the European perspective by simultaneously
launching national reports. The events enjoyed a high profile with the participation of Ministers
and other senior officials in the drugs field. The EMCDDA provided human and logistical
support for these events according to the requirements of the national authorities.
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Chapter 3
Supporting activities 
Administrative support
Planning, evaluation and legal matters
The EMCDDA introduced ABM-based tools for planning, monitoring, and reporting, including
legal advice and assistance some years ago. In 2004, work focused on improving the reporting
system (more frequent progress reporting on the execution of the annual budget/work
programme), updating the internal procedures for internal management and control, the legal
aspects to do with the implementation of the reform of the staff regulations and the operations
required to cope with the inadequacy of the EMCDDA current premises (namely renting
supplementary working space, and building and leasing a new building). 
In mid 2004, the EMCDDA participated actively in the working group on the Evaluation of
Community Agencies which was set up and chaired by the Evaluation Unit of DG Budget of the
European Commission. The purpose of this working group was to prepare guidance on
common evaluation questions for future Agency evaluations and to discuss ways of enhancing
cooperation between evaluation staff in the Agencies and the European Commission.
At the beginning of November 2004, the EMCDDA received the first visit of the European
Commission’s Internal Audit Service to prepare the audit of the EMCDDA internal control system
to be carried out in January 2005, in accordance with the financial regulation applicable to the
EMCDDA.
Human and material resources 
Human resources
Activity in this area focused on implementing the reform of the EU Staff regulations which
entered into force on 1 May 2004. In this context, the EMCDDA adopted a series of
implementing rules based on the ones adopted by the European Commission. The EMCDDA
participated as a member in the working group that was set up and chaired by DG ADMIN of
the European Commission to define, as far as possible, a common approach for the Agencies
in the implementation of the recent reform of the staff regulations.
The selection procedure for the appointment of the new EMCDDA executive Director was
launched in March 2004 with the publication of a Call for applications in the EU Official
Journal (C 56 A of 04/03/04). In early 2005, in accordance with the EMCDDA founding
regulation, the EMCDDA Management Board is expected to decide on the appointment of the
executive Director for a five-year renewable term on the basis of a proposal from the European
Commission.
The table below shows the breakdown by category, grade, nationality and sex of staff
employed by the EMCDDA at the end of 2004.
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Breakdown by category, grade, nationality and sex of staff employed by the EMCDDA in
2004
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Auxiliary staff
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Contract staff
Property assets and logistics
In order to cope, in the short term, with urgent needs for supplementary working space arising
from the lack of space in the EMCDDA’s current premises in Lisbon, the Centre rented
supplementary offices in Lisbon and moved a contingent of its staff there.
On 28 July 2004, the EMCDDA and the European Maritime Safety Agency (EMSA) signed a
Memorandum of Understanding (MoU) with the Portuguese Government for the construction of
new premises for the two agencies, on a plot of land located in Lisbon (Cais do Sodré) under
the jurisdiction of Lisbon Port Authority. According to this MoU, the EMCDDA will rent for a
period of 25 years a building of 3,500 m2 with 90 parking places and will share with EMSA
common premises of 2,000 m2, both to be delivered key in hand. On 6 August 2004, the
EMCDDA submitted this operation to the Budgetary Authority. On 16 September 2004, the
European Parliament informed the Centre that it had no objections. The Council of the
European Union issued no opinion.
Budget, financial and accounting management
At the end of 2004, the EMCDDA financial management service was provided with adequate
reinforcement of its working capacity through the assignment of a second initiating officer and
the recruitment of an assistant accountant. 
In this context, the EMCDDA has pursued the development and improvement of its procedures
for internal control and management, with special attention paid to the standardisation of its
contractual instruments and processes, the development of its tools for ex-ante verification
(check lists) and the assessment of the use of its committed appropriations (‘RAL’).
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The EMCDDA was a member of the EU inter-institutional working group set up to define the
new rules for accrual accountancy, in accordance with the financial regulation applicable.
A budget of €12,244,030 was adopted for the implementation of the 2004 work programme
(EU-25).
The budgetary figures for 2004 are presented in the tables below.
Budgetary provisions and appropriations, 2004
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EMCCDA balance sheet at 31.12.2003 – Assets
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EMCDDA budget: Out-turn accounts
Revenue and expenditure at 31.12.2003r
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Documentation 
The main objective of the Library and Documentation Centre is to provide a high quality
internal information service on drugs and drug addiction covering all EMCDDA working areas.
In 2004, the EMCDDA library pursued its efforts in the transition from the old to the new
documentary software – WinLib2000 – for the management and parameterisation of its
bibliographic online catalogue (Bibliodatabase). The Bibliodatabase quality control, comprising
both the data management process as well as the searches issues, was finalised and
preparation for its launch on the Internet was underway. 
The main activities focused on the following areas:
• selection, acquisition, cataloguing, indexing and dissemination of documentary material
(monographs, journals, specialised articles, reference, newspapers, CD-ROMs, etc), making
available useful information in either paper or electronic format to EMCDDA staff; 
• intranet service: electronic dissemination of the journals collection and updating and
launching of the new software version of Bibliodatabase, the EMCDDA bibliographic
catalogue, managed by WinLib2000;
• users’ services: circulation of publications, bibliographical retrieval in internal and external
databases, management of loans, DSI (dissemination of information by profile) and monthly
publication of the ‘Journals’ table of contents’;
• external users: reply to information and documentation requests thereby offering to the target
external scientific and professional audiences a reference service on the drug phenomenon at
European level;
• participation in networking projects and activities with European partners.
Information technology 
IT infrastructures and services
In February 2004, due to lack of space, a second site for the EMCDDA offices was opened in
Almirante Reis, Lisbon and in September 2004, a ‘Bureau de Passage’ was opened in Brussels.
A Windows domain upgrade from NT to 2003 with active directory was finalised in March
and has enabled coherent implementation of profiles, applications and information resources
covering the two sites in Lisbon and in Brussels. The topology of the two sites has also been
exploited to implement backup disaster recovery components.
Optimisation work was carried out at the level of the Storage Area Network (SAN) that has
increased capacity and accessibility of the Windows server storage.
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The budget execution system, SI2, was transformed onto a hot standby dual server
configuration. This configuration will minimise recovery time in case of hard/soft malfunction of
the main server.
The hardware and software for the email server were upgraded and a new system for backup
restoration of individual mailboxes was introduced which minimises the time needed for
restoring data. A system for an infinite mailbox concept is also under preparation.
The Oracle databases were consolidated on two servers: one for Windows (administrative
information systems), the other one on SUN Solaris (EMCDDA dissemination on the internet).
A revised anti-virus strategy was implemented and is now based on two different constructors
corporate anti-virus systems running on separate servers, and on a different workstation-based
anti-virus software.
Server based applications are now using the Citrix technology. This was combined with the
regular and centralised distribution of security patches, in order to increase workstation security.
Two major corporate licensing contracts were signed with Oracle and Microsoft.
Electronic dissemination systems
The main objectives for 2004 were: the integration of a content management system for the
EMCDDA websites; the 2004 Annual report online; Snapshot 2004; the introduction of the
Statistical bulletin; and EISDD online Table 1.
A content management application (CMA) was introduced for EMCDDA users, with which they
can author and publish sections on the EMCDDA websites. The system supports a common
layout for different web sites, and features modular extensibility based on the common
EMCDDA software project guidelines. Extensive user training was carried out and continuous
improvement is underway.
A main development to support enlargement was the additional production languages and their
implications for the technical environment for IT. A particular advantage of the CMA is the
automatic handling of multilingual pages, where each page can have several language
versions without the need to translate whole website sections.
The modular development approach was increased and in this sense further development was
started on the CMA in order to integrate existing or other new web development projects.
SVN was introduced as a source control system to allow multiple contractors continuous work
on development projects.
The interactive Annual report online was published in 20 languages. Online data collection
tools were developed and introduced for the continuation of the Snapshot project, i.e. the
Snapshot 2004.
The EISDD online interface for Standard table 1: ‘Basic results and methodology of population
surveys on drug use’ was accepted as the first online data collection for the focal points.
Mail and directory services as well as Solaris operating system versions were upgraded on
several servers, EDDRA was migrated, and ultra450 decommissioned.
Test installation on a Tamino server was set up in order to investigate possibilities of XML-based
data storage and retrieval system.
Publication title
4
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Chapter 4
Statutory bodies
Management Board
Activities and main decisions 
At the 27th meeting of the Management Board in Lisbon on 14–16 January 2004, the Board
adopted the General report of activities 2003, the three-year work programme 2004–2006,
the work programme for 2004 and a budget of EUR 12,244,030 for 2004. At the meeting, the
Management Board examined a preliminary draft budget for 2005 on the basis of an EU
subsidy of MEUR 12.9, which was adopted by written procedure after the meeting. The
Management Board mandated its Chairman to negotiate with the Portuguese government and
the European Maritime Safety Agency (EMSA) the possibility to house both the EMCDDA and
the EMSA in the same location. The impact and visibility of the 2003 Annual reports was
discussed, and the suggestion to present the Annual report in the Member States was
welcomed. The Board proposed that the report could also be presented separately to the
Ministers of Health, of Justice and Home Affairs. The Management Board adopted the mandate
and composition of the Budgetary Committee, as well as the revised internal rules of procedure
of the Board except two articles to be adopted in the next meeting. The Board elected for
another year Mr Brunson (BE) and Mr Lawrence (UK) as members of the Bureau. Mr Gillard
(BE) and Mr Pietsch (AT) were elected as members of the Budgetary Committee. It was decided
to elect the third member to the Bureau and the Budgetary Committee in July when the
accession countries would be full members of the European Union and the Board. The
Management Board adopted the profile of the new Director.
Representatives of the new Member States after the enlargement of the European Union
participated, for the first time, as full members in the Management Board meeting of 7–8 July
2004. Ms. Gábor (HU) was elected member of the Bureau, and M. Veresies (CY) member of
the Budgetary Committee. The Management Board discussed the financial perspectives for
2005 and 2006, and adopted a resolution to be transmitted by the Chairman to all members
of the European Parliament. In this resolution, the Board expressed its concern with regard to
the impact that the MEUR 12 foreseen in the preliminary draft Community budget for 2005
could have on the operational capacity of the Centre, and expressed the wish that the
Budgetary Authorities reconsider the level of appropriations proposed for the EMCDDA. The
Board was informed by the European Commission on the state of progress of the procedure for
nomination of the new Director. The Board adopted a document on external relations of the
EMCDDA, as well as implementing rules in the framework of the reform of the staff regulations
of the European Commission. It was agreed to postpone the decision to nominate a new
Scientific Committee until the adoption of the recast of the founding regulation of the EMCDDA,
to extend its current mandate and to invite the new Member States to nominate their
representatives. The Board further decided to set up a small working group to thoroughly
examine the rules of procedure of the Management Board and to come up with a proposal at
the next meeting. 
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Bureau 
Activities and main decisions 
In 2004, the Bureau met four times in Lisbon, and once in Brussels (3). 
At its meeting of 17 February, the time schedule for production and presentation of the 2004
Annual report  was adopted unanimously. The Bureau discussed the preliminary draft budget
for 2005 and established a first agenda for the Management Board meeting in July. 
On 27 May 2004, the Bureau revised the draft agenda for the next Management Board
meeting and discussed several items concerning the practical organisation of Board meetings,
such as the attendance of observers. The European Commission informed the Bureau on the
budgetary procedure for 2005 and the context of financial constraints. The Bureau agreed that
a strategic document with different budgetary scenarios should be prepared by the EMCDDA,
endorsed by the Bureau and sent to the Board for discussion in July. 
An extraordinary Bureau meeting took place on 9 September in Brussels. The objective of this
meeting was to examine various points of concern raised by several Board members
concerning the delegation of competences decided upon by the Director on 13 July 2004. 
On 12 October, the Bureau recommended that the interim period from the end of the mandate
of the leaving Director until the nomination of a new director should be assured by Mr Jaume
Bardolet, staff member with the highest seniority and highest grade, to be confirmed by the
Management Board. It was agreed to launch a silent procedure for adoption by the
Management Board to transfer EUR 244 000 from Title 1 to Title 2 of the budget. The Bureau
considered that different budgetary options for a MEUR 12 budget for 2005 should be
submitted to the Budgetary Committee and the Bureau in order to give the Management Board
sound orientations for the adoption of the 2005 budget. The Bureau noted the interest in
exploring ways of strengthening collaboration between the EMCDDA and ESPAD (the
European school survey project on alcohol and other drugs).
At its meeting on 8 December, the Bureau mainly prepared the forthcoming Management
Board meeting in January 2005 and commented upon draft documents. 
Scientific Committee
Activities, main discussion points and results
In 2004, the EMCDDA staff provided regular support to the Scientific Committee Chairperson
and all members. The Scientific Committee members were kept consistently informed and their
opinion sought on appropriate scientific matters. Two Scientific Committee meetings were
technically and logistically organised, as follows:
• 21st regular meeting of the Scientific Committee on 26 April 2004, Lisbon; and
• 22nd regular meeting of the Scientific Committee on 6–7 December 2004, Lisbon
The main task of the Scientific Committee in 2004 was to provide a formal opinion on the
Centre’s 2005 work programme. The Committee welcomed the work programme recognising
that it fits well into the strategic objectives of the Centre’s 2004–2006 three-year work
(3) 17 February (Lisbon), 27 May (Lisbon), 9 September (Brussels), 12 October (Lisbon), 8 December
(Lisbon).
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programme. Furthermore, the Committee noted the improvement in the structure of the 2005
work programme with an increased focus on quality assurance, consolidating the process of
integrating the new Member States and recognising the increased training needs. 
Individual Committee members provided feedback and advice on the draft 2004 Annual report.
The Committee, as a whole, also endorsed the more integrated version 2004 of the Annual
report and the supporting Statistical bulletin as evidence of greater transversal cooperation
between programmes. It was recommended that this should be further sustained, encouraged
and recognised. The Committee also emphasised the importance of EMCDDA’s technical expert
meetings, which give continuous relevance and freshness to its scientific activities and expressed
its readiness to support the Centre’s quality assurance efforts.  
Following the wish expressed by the Scientific Committee in its formal opinion on the
2004–2006 three-year work programme, some members consulted the draft Europol–EMCDDA
Snapshot for the evaluation of the EU strategy and action plan on drugs (2000–2004).
Furthermore, although not formally involved, and being aware of the procedural and time
limitations, in the preparation of the forthcoming EU action plan on drugs, the Scientific
Committee provided a short opinion to the Commission on the role of scientific evidence in the
formulation of this important EU instrument. Among others, the Committee stressed that
appropriate scientific approaches should be adopted that allow the action plan to be
adequately assessed and when defining objectives and targets it is essential to take into
consideration the capacities and strengths of existing information systems.
In September 2004, as it is stipulated by the EMCDDA Regulation currently in place, the
Chairman of the EMCDDA Management Board sent an official letter inviting all new Member
States to appoint Scientific Committee members. By the end of 2004, six of the new Member
States have already officially appointed their representatives – Estonia, Latvia, Lithuania, Malta,
Poland and Slovakia; whereas Cyprus, the Czech Republic, Hungary and Slovenia are
expected to do so shortly.
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EMCDDA internal management and control system 
Overview of the EMCDDA's 2004 internal management and control procedures 
In accordance with the financial regulation applicable to the EMCDDA, which transposes
integrally the text of the Framework financial regulation nº2343/2002, the EMCDDA has set its
internal procedures for budget execution and internal control, while defining and implementing
a partially decentralised management model. 
As a consequence both operational and financial decisions required for the implementation of
the EMCDDA work programme and budget have been decentralised by delegation to the
Coordinator of the Programmes on which the EMCDDA activities and working organisation
relies. 
The administrative services provide support to operational managers for financial management
and ensure internal planning and monitoring, as well as ex ante verification of the transactions. 
These procedures have been codified and all Programme coordinators/deputy authorised
officers have received specific training and information on their role duties and liability, in
accordance with the relevant provisions of the financial and staff regulations.
The key actors and steps of the EMCDDA procedures for budget execution can be summarised
as follows:
• Project manager: initiative and operational input for the administrative and financial
operations required to implement projects (technical specifications for tendering procedures,
cost estimate, "certified correct" for payments). 
• Financial helpdesk team: preparation of the required administrative and contracting
supporting documents with the input of the Project manager concerned.
• Planning, evaluation and legal matters team: checking of compliance with work programme
and budget adopted and legal assessment of the operation.
• SI2 initiating officers:  SI2 operations in the EMCDDA SI2 electronic management and
accounting system to prepare the decision of the Authorising officer. 
• Verifying officer: ex ante verification. 
• Programme coordinator: authorisation of the required budgetary and legal operations, acting
as deputy authorising officer for the execution of the programme concerned.
• Accountant: execution of the required financial transactions.
The above-mentioned procedures are consistent with the EMCDDA project-based working
methods aimed at integrating activities and resources management, in accordance with the
ABM/ABB principles.
In this context, the Centre has established procedures for planning, monitoring and reporting,
with a clear indication of the actors involved, their role and responsibilities.
Following the adoption by the EMCDDA Management Board, in January 2003, of the new
'Operating framework for the Reitox system' a new grant agreement model was introduced for
the annual co-financing of the activities of the Reitox national focal points, which fully complies
with the relevant provisions of new financial regulation applicable to the EMCDDA. This
agreement requires that an external annual audit has to be carried out by an independent
body or expert officially authorised to carry out audits of accounts in order to certify that the
Annexes
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financial documents submitted to the EMCDDA by the beneficiary comply with the financial
provisions of the agreement, that the costs declared are the actual costs, and that all receipts
have been declared. 
The European Court of Auditors and the European Anti-Fraud Office (OLAF) enjoy the right of
access for the purposes of checks and audits.
Taking into account the current dimension of the EMCDDA's activity and structure and
considering the budgetary constraints, the EMCDDA has not set up its own internal audit
capability, relying for this function on the Commission's Internal Auditor, in accordance with the
applicable financial regulation.
Main facts/events in 2004 with regard to the EMCDDA's internal management and
control system
In 2004, the EMCDDA pursued the development and improvement of its management and
control system through the following measures:
• strengthening the working capacity of its financial helpdesk (full assignment of a second staff
member) and accounting service (recruitment of an assistant accountant);
• more frequent and structured progress reporting (on a weekly basis) of the execution of the
budget appropriations earmarked for the implementation of the EMCDDA work programme;
• permanent monitoring of the above-mentioned execution and periodical assessment with the
managers concerned/deputy authorising officers, and final evaluation of the use of the 2004
appropriations, with special attention paid to the use of the committed appropriations (RAL),
in order to optimise the rate of execution and to define, as accurately as possible, the actual
needs for eventual carry-overs;
• development of the intranet-based financial helpdesk to promote better knowledge and more
effective use by those concerned of the EMCDDA instruments and procedures for
management and internal control;
• further standardisation of the tendering/contracting instruments and procedures, in
accordance with the relevant financial regulation, to reduce the risks entailed by these
operations;
• specific training sessions for deputy authorising officers and dependent staff on
tendering/contracting rules and procedures and on rules for refunding participants in
EMCDDA meetings;
• definition and implementation of formal checklist to document the various steps/subjects of
the ex ante verification of the financial transactions;
• further rationalisation of the contractual policy, with special attention to the assessment of the
needs and procedures to be implemented in the area of the logistics and management of
movable and immovable property;
• definition of an action plan to improve the overall working atmosphere/environment at the
EMCDDA, building on the assessment of the EMCDDA internal reform adopted at the end of
2000.
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Outputs 
Publications
Annual report 2004: the state of the drugs problem in the European Union and Norway
A yearly overview of the drug phenomenon in the EU Member States and Norway.
Available in 20 languages - all EU official languages (except Maltese).
Cat. No.: TD-AC-04-001-
CS/DA/DE/EN/ES/ET/FI/FR/GR/HU/IT/LT/LV/NL/NO/PL/PT/SK/SL/SV-C
http://www.emcdda.eu.int/?nnodeid=419
Also available as a 20-language website with additional explanatory material, graphics and
data sources http://ar2004.emcdda.eu.int
General report of activities 2003
A detailed progress report of the EMCDDA's activities over a 12-month period.
Available in EN.
http://www.emcdda.eu.int/?nnodeid=426
Drugnet Europe 
The EMCDDA's newsletter, provides regular, rapid and succinct information on the Centre's
activities to a broad readership.
4 editions (45, 46, 47, 48) 
Available in ES, DE, EN, FR, PT.
http://www.emcdda.eu.int/?nnodeid=411
EMCDDA Drugs in focus
Issue 12, 'Evaluation of the European Union's strategy and action plan (2000-2004)' 
Issue 13, 'Overdose - a major cause of avoidable death among young people' 
Issue 14, 'Comorbidity - drug use and mental disorders' 
Drugs in focus is the title of a series of policy briefings from the EMCDDA, designed to offer
policy-makers the latest findings on key issues in the drugs field and to inform the decision-
making process in this domain. 
Available in 21 languages.
http://www.emcdda.eu.int/?nnodeid=439
EMCDDA Insights, No 6 
An overview of cannabis potency in Europe
The EMCDDA's Insights are volumes conveying the findings of study and research carried out
by the agency on topical issues in the drugs field.
Cat. No: TD-60-04-030-EN-C
Available in EN.
http://www.emcdda.eu.int/?nnodeid=429
EMCDDA Monographs, No 7
Hepatitis C and injecting drug use: impact, costs and policy options
The EMCDDA Monographs are specialised publications containing scientific papers prepared in
the context of EMCDDA research studies, conferences and seminars.
Available in EN. 
http://www.emcdda.eu.int/?nnodeid=428
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EMCDDA Risk assessments 
No 6, Report on the risk assessment of 2C-I, 2C-T-2 and 2C-T-7 in the framework of the joint
action on new synthetic drugs 
No 7, Report on the risk assessment of TMA-2 in the framework of the joint action on new
synthetic drugs 
The Risk-assessment reports record the results of the agency's work under the terms of the Joint
Action on new synthetic drugs, formally adopted by the Council of the EU in 1997.
Available in EN.
http://www.emcdda.eu.int/?nnodeid=431
Marketing materials 
General presentation brochure
The brochure describes the agency's main activities, areas of expertise as well as its founding
mandate and objectives.
Now available in 21 languages.
http://www.emcdda.eu.int/?nnodeid=433
EMCDDA online' promotional brochure
This brochure publicises the EMCDDA's latest online products.  
Available in EN.
http://www.emcdda.eu.int/?nnodeid=6041
Joint agencies' brochure European agencies – working across Europe for you 
Available in 23 languages.
http://www.emcdda.eu.int/?nnodeid=438
News releases
11 news releases (totalling 94 products). 
No 1 – Hepatitis C – The 'hidden epidemic' 
A major challenge to public health', warns EU drugs agency
(4.2.2004)
No 2 – Russian delegation visits EU drugs agency 
EU's largest neighbour exchanges know-how with EMCDDA
(6.5.2004) 
No 3 – The way forward for EU action against drugs 
EU drugs agency plays key role in evaluation 
(10.5.2004)
No 4 – International day against drugs 
Drug treatment now more available, accessible and diverse
(25.6.2004)
No 5 – International day against drugs 
New EMCDDA study asks 'Is cannabis getting stronger?'
(25.6.2004)
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No 6 – Evaluation of the EU strategy and action plan on drugs (2000 -2004) 
'Snapshots' shed light on EU targets
(26.10.2004) 
No 7 – 2004 Annual report from the EU drugs agency 
(4.11.2004) 
No 8 – 2004 Annual report: Highlights
Signs of progress: decline in drug deaths, new HIV infections and heroin use but increasing
worries about rising use of other drugs 
(25.11.2004) 
No 9 – 2004 Annual report: 'Selected issues'
EMCDDA looks behind rising numbers of young people in cannabis treatment 
(25.11.2004)
No 10 – 2004 Annual report: 10 years of reporting
Information on drugs 'increasingly robust' in the enlarged Union, says EMCDDA 
(25.11.2004)
No 11 – Hepatitis C and injecting drug use: impact costs and policy options 
Hepatitis C may cost countries billions of EURO in healthcare 
(15.12.2004)
http://www.emcdda.eu.int/?nnodeid=6771
3 Fact sheets (EN) 
Fact sheet 1: New online pool of national drug information
Fact sheet 2: New feature on ELDD offers easy access to EU drug legislation
Fact sheet 3: Evaluation of the EU strategy and action plan on drugs (2000-2004)
http://www.emcdda.eu.int/?nnodeid=2236 
Press reviews
4 quarterly press reviews
1 ad hoc press review (Chairman's visit to Czech Republic)
1 three-volume 800-page Annual report press review
Websites
EMCDDA public website
The gateway to drug information in Europe.
The website was completely overhauled and restructured in 2004.
http://www.emcdda.eu.int 
Annual report 2004
The multilingual Annual report website offers full online version of the report in 20 languages
and a wealth of additional interactive graphics, statistics and press materials.
http://ar2004.emcdda.eu.int
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Statistical bulletin 2004
The bulletin is a companion publication to the EMCDDA Annual report and provides a
complementary information source. It supplies the user with the data tables collated by the
EMCDDA from the information submitted by the national focal points Reitox network. These
tables constitute the epidemiological basis on which the annual report is written and are
frequently referenced by it. In addition to the tables of data and the accompanying graphics,
the bulletin gives detailed technical commentaries, notes and descriptions.
http://stats04.emcdda.eu.int
Country situation summaries
Country situation summaries are available for 25 Member States and Norway. They offer a rich
pool of national drug data in Europe. Their main purpose is to provide brief synopses of up-to-
date national data and trends. They also include selected links to other national information
sources.
http://profiles.emcdda.eu.int/?nnodeid=1966
Snapshot 
To help policy-makers shed light on the progress of the goals of the EU drug strategy (2000-
2004), the EMCDDA, in collaboration with Europol, drew up a 'snapshot' of the drug situation
and policy measures at the strategy's outset and close. The snapshot website offers data on the
drug situation by country as well as downloadable reports and thematic papers. 
http://snapshot.emcdda.eu.int
European legal database on drugs
The European Legal Database on Drugs (ELDD) is the EMCDDA's online database of
information on European drugs-related legislation for the EU Member States and Norway.
http://eldd.emcdda.eu.int
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